Journal
ATHEROSCLEROSIS
Volume 240, Issue 1, Pages 260-271Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2015.03.025
Keywords
SLCO1B1; Anti-HMGCR; Statin-related myopathy; Pharmacogenomics
Funding
- Pollin Cardiovascular Prevention Fellowship
- Marie-Josee and Henry R. Kravis endowed fellowship
- NIH training grant [T32HL07024]
Ask authors/readers for more resources
Statin-related myopathy (SRM) undermines drug adherence that is critical for achieving the benefits of lipid-lowering therapy. While the exact mechanism of SRM remains largely unknown, recent evidence supports specific genetic and immunologic influence on the development of intolerance. Genes of interest include those involved in the pharmacokinetics of statin response (i.e. drug metabolism, uptake transporters, and efflux transporters), pharmacodynamics (i.e. drug toxicity and immune-mediated myopathy), and gene expression. We examine the influence of genetic and immunologic variation on the pharmacokinetics, pharmacodynamics, and gene expression of SRM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available